Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors

BACKGROUND: In patients with epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC), epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) treatment has shown a good response. Subsequent treatments jeopardize the ability to determine the effect of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thorac Cancer
Autors principals: Imai, Hisao, Kaira, Kyoichi, Mori, Keita, Kotake, Mie, Mitani, Masumi, Kawashima, Naoko, Hisada, Takeshi, Minato, Koichi
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons Australia, Ltd 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6885435/
https://ncbi.nlm.nih.gov/pubmed/31595714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13193
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars